Par Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Par Drugs and Chemicals Limited's Board approved its audited financial results for Q4 and FY2025-26 ended March 31, 2026. The statutory auditor issued an UNMODIFIED (clean) opinion on the standalone financial results. However, the Auditor's Report identified a Key Audit Matter regarding the company's ability to continue as a going concern due to SEBI's Ex-Parte Interim Order and Confirmatory Order restraining the proposed Business Transfer Arrangement (BTA) involving slump sale of the primary business to a related party. The company is evaluating legal remedies to challenge these orders. No outstanding defaults on loans or debt securities were reported. The board also renewed banking facilities of Rs. 161 lakh with Kotak Mahindra Bank and authorized investments up to Rs. 90 crore in liquid/arbitrage funds and fixed deposits.
While the auditor issued a clean opinion, the SEBI regulatory order blocking the business transfer remains a significant uncertainty that could impact the company's future operations and strategy. Shareholders should monitor the outcome of the company's legal challenge to SEBI's orders.